Sen­ate bill to cut health costs, tar­gets FDA tweaks

The Sen­ate Health, Ed­u­ca­tion, La­bor and Pen­sions (HELP) com­mit­tee on Thurs­day un­veiled a dis­cus­sion draft of a new wide-rang­ing bill to help cut health care costs.

The draft in­cludes nine sec­tions re­lat­ed to the FDA, in­clud­ing ef­forts mir­ror­ing House-passed bills re­form­ing the Or­ange Book and Pur­ple Book, as well as ini­tia­tives to in­crease gener­ic drug com­pe­ti­tion.

For­mer FDA Com­mis­sion­er Scott Got­tlieb praised the Sen­ate draft: “These mea­sures WILL low­er prices. The most tan­gi­ble set of bi­par­ti­san re­forms to emerge.”

Among the pro-com­pet­i­tive pro­vi­sions, the draft seeks to pre­vent first-to-file gener­ic drug ap­pli­cants from block­ing, be­yond the 180-day ex­clu­siv­i­ty pe­ri­od grant­ed by the FDA, the en­trance of sub­se­quent gener­ics. An­oth­er pro­vi­sion would al­so trig­ger the start of the first-to-file gener­ic drug ap­pli­cant’s 180-day ex­clu­siv­i­ty when a sub­se­quent ap­pli­cant has been ten­ta­tive­ly ap­proved and the first-to-file ap­pli­cant has not re­ceived fi­nal ap­proval with­in 30 months of sub­mit­ting its ap­pli­ca­tion.

The bill al­so tight­ens the de­f­i­n­i­tion for el­i­gi­bil­i­ty for five-year new chem­i­cal en­ti­ty (NCE) ex­clu­siv­i­ty to pre­vent ever­green­ing, clar­i­fy­ing that the ex­clu­siv­i­ty is avail­able on­ly for a drug con­tain­ing no ac­tive moi­ety that has been pre­vi­ous­ly ap­proved in the US.

Sev­er­al oth­er pro­vi­sions would al­so help biosim­i­lar man­u­fac­tur­ers.

For in­stance, the bill would pre­vent de­lays re­lat­ed to com­pli­ance with USP stan­dards by ex­clud­ing all bi­o­log­ics sub­ject to reg­u­la­tion un­der the Pub­lic Health Ser­vice Act from re­quire­ments to fol­low USP com­pen­di­al stan­dards.

The bill al­so ad­dress­es the tran­si­tion next March for cer­tain bi­o­log­ics ap­proved un­der new drug ap­pli­ca­tions, clar­i­fy­ing that such prod­ucts, in­clud­ing in­sulin prod­ucts, can­not re­ceive new, ex­tend­ed mar­ket ex­clu­siv­i­ties.

At the same time, the bill pre­serves cer­tain un­ex­pired ex­clu­siv­i­ties for bi­o­log­ics un­der­go­ing the tran­si­tion and en­sures that mar­ket­ing ap­pli­ca­tions sub­mit­ted six months pri­or to the tran­si­tion that are still un­der FDA re­view at the time of the tran­si­tion date will not have to be re­sub­mit­ted.

The bill al­so goes af­ter phar­ma­cy ben­e­fit man­agers (PBMs), pre­vent­ing them from en­gag­ing in spread pric­ing, or charg­ing a plan spon­sor, health in­sur­ance plan or pa­tient more for a drug than the PBM paid to ac­quire the drug. An­oth­er pro­vi­sion would re­quire PBMs to pass on 100% of any re­bates or dis­counts to the plan spon­sor.

Sep­a­rate­ly, the House Ways & Means Com­mit­tee float­ed a draft bill on Thurs­day to es­tab­lish an out-of-pock­et cap for Medicare ben­e­fi­cia­ries.

Dis­cus­sion Draft


First pub­lished in Reg­u­la­to­ry Fo­cus™ by the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety, the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care prod­ucts. Click here for more in­for­ma­tion.

Im­age: Shut­ter­stock

Author

Zachary Brennan

managing editor, RAPS

UP­DAT­ED: Roche bags 'break­through' an­ti-fi­bro­sis drug in $1.4B biotech buy­out deal

Roche is snapping up a “breakthrough” anti-fibrotic drug in a $1.4 billion buyout.

The pharma giant announced Friday that it is acquiring Promedior, primarily to get its hands on PRM-151, a recombinant form of human pentraxin-2 (PTX-2) protein that has nailed down mid-stage clinical data on idiopathic pulmonary fibrosis and demonstrating its potential for a range of fibrotic conditions.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.

(Image: Associated Press)

Amarin emerges from an ex­pert pan­el re­view with a clear en­dorse­ment for Vas­cepa and high odds of suc­cess when the FDA weighs in for­mal­ly

Several FDA experts who gathered Thursday to consider the landmark approval of Vascepa to reduce cardio events in an at-risk population voiced their unease about various aspects of the efficacy and safety data, or ultimately the population it should be used to treat. But the overwhelming belief that the data pointed to the drug’s benefit and clearly outweighed risks carried the day for Amarin.

The panel voted unanimously (16 to 0) to support the company’s positive data presentation — backing an OK for expanding the label to include reducing cardio risk. The vote points Amarin $AMRN down a short path to a formal decision by the FDA, with the odds heavily in its favor. Chances are the rest of the questions about the future of this drug will be hashed out in the label’s small print.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.

Federal Trade Commission commissioner Rohit Chopra testifies on Capitol Hill (AP Photo/Susan Walsh)

FTC clears Bris­tol-My­ers’ $74B deal to buy Cel­gene — but Dems sig­nal a po­ten­tial hard shift against Big Phar­ma M&A

Bristol-Myers Squibb’s record $74 billion takeover of Celgene is a done deal. And it will all be over — except for the lingering complaints from die-hard Celgene investors — on Wednesday.

Like much else that’s going on in Washington these days, the vote among the 5 FTC commissioners split along party lines, with the 3 Republicans voting to clear the way and the 2 Democrats steamed over what they see as a major M&A move that will lessen competition and innovation. And that split has big implications for the M&A side of the business if the Dems take the White House in 2020.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.

No­var­tis spin­out’s first an­ti-ag­ing PhI­II is a flop, so now they’ll turn to Parkin­son’s chal­lenge as shares wilt

Novartis spinout resTORbio is grappling with the collapse of its lead clinical program this morning — an anti-aging R&D failure that will badly damage their rep in the field.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.

BeiGene CEO John Oyler at an Endpoints event in Shanghai, October 2018 (Credit: Endpoints News/PharmCube)

UP­DAT­ED: In a first, FDA green-lights use of a Chi­nese built can­cer ther­a­py — and more are com­ing

Weeks after Amgen took a $2.7 billion stake in BeiGene, the Beijing-based biotech has secured its first-ever FDA approval for zanubrutinib, a BTK inhibitor, months ahead of schedule.

BeiGene’s drug, branded as Brukinsa, has secured accelerated approval for adult patients with mantle cell lymphoma (MCL) — a typically aggressive, rare, form of blood cancer — who have received at least one prior therapy.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.

What does $62B buy you these days? A lot, says Take­da ex­ecs as the phar­ma play­er promis­es a block­buster R&D fu­ture

First comes the $62 billion buyout. Then comes the asset auction and reorganization to pay down debt. Now comes the detailed pledge of a bigger, brighter future in drug development.

That’s where Takeda finds itself on R&D day today, about 11 months after closing on their Shire acquisition. R&D chief Andy Plump is joining CEO Christophe Weber and other top members of the team to outline a new set of priorities in the greatly expanded pipeline at Takeda, which has jumped into the top ranks of the world’s pharma giants in the wake of the Shire deal.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.

GSK's asth­ma bi­o­log­ic Nu­cala scores in rare blood dis­or­der study

GlaxoSmithKline’s asthma drug Nucala, which received a resounding FDA rejection for use in chronic obstructive pulmonary disease (COPD) last year, has shown promise in a rare blood disorder.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.

Mer­ck buys a fledg­ling neu­rode­gen­er­a­tive biotech spawned by an old GSK dis­cov­ery al­liance. What’s up with that?

Avalon Ventures chief Jay Lichter has a well-known yen for drug development programs picked up in academia. And what he found in Haoxing Xu’s lab at the University of Michigan pricked his interest enough to launch one of his umbrella biotechs in San Diego.

Xu’s work laid the foundation for Avalon to launch Calporta, which has been working on finding small molecule agonists of TRPML1 (transient receptor potential cation channel, mucolipin subfamily, member 1) for lysosomal storage disorders. And that pathway, they believe, points to new approaches on major market neurodegenerative diseases like Parkinson’s, ALS and Alzheimer’s.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.

(Image: Associated Press)

No­var­tis scores its lat­est FDA OK — this time for a new sick­le cell dis­ease drug picked up in a $665M deal

Novartis’ decision to buy Oklahoma-based biotech Selexys 3 years ago for up to $665 million has paid off with an FDA approval today.

Blessed with the FDA’s breakthrough drug designation for a speedy review, the pharma giant has pinned down an approval for crizanlizumab, a new therapy designed to reduce the frequency of painful incidents of vaso-occlusive crises among sickle cell disease patients 16 or older.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.